Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Florian Hornsteiner und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund FWF, Österreichische Forschungsförderungsgesellschaft, Österreichischen Akademie der Wissenschaften.
Abstract (Originalsprache)
Background
Tumor-targeted therapy causes impressive tumor regression, but the emergence of resistance limits long-term survival benefits in patients. Little information is available on the role of the myeloid cell network, especially dendritic cells (DC) during tumor-targeted therapy.
Methods
Here, we investigated therapy-mediated immunological alterations in the tumor microenvironment (TME) and tumor-draining lymph nodes (LN) in the D4M.3A preclinical melanoma mouse model (harboring the V-Raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutation) by using high-dimensional multicolor flow cytometry in combination with multiplex immunohistochemistry. This was complemented with RNA sequencing and cytokine quantification to characterize the immune status of the tumors. The importance of T cells during tumor-targeted therapy was investigated by depleting CD4 + or CD8 + T cells in tumor-bearing mice. Tumor antigen-specific T-cell responses were characterized by performing in vivo T-cell proliferation assays and the contribution of conventional type 1 DC (cDC1) to T-cell immunity during tumor-targeted therapy was assessed using Batf3 −/− mice lacking cDC1.
Results
Our findings reveal that BRAF-inhibitor therapy increased tumor immunogenicity, reflected by an upregulation of genes associated with immune activation. The T cell-inflamed TME contained higher numbers of activated cDC1 and cDC2 but also inflammatory CCR2-expressing monocytes. At the same time, tumor-targeted therapy enhanced the frequency of migratory, activated DC subsets in tumor-draining LN. Even more, we identified a cDC2 population expressing the Fc gamma receptor I (FcγRI)/CD64 in tumors and LN that displayed high levels of CD40 and CCR7 indicating involvement in T cell-mediated tumor immunity. The importance of cDC2 is underlined by just a partial loss of therapy response in a cDC1-deficient mouse model. Both CD4 + and CD8 + T cells were essential for therapy response as their respective depletion impaired therapy success. On resistance development, the tumors reverted to an immunologically inert state with a loss of DC and inflammatory monocytes together with the accumulation of regulatory T cells. Moreover, tumor antigen-specific CD8 + T cells were compromised in proliferation and interferon-γ-production.
Conclusion
Our results give novel insights into the remodeling of the myeloid landscape by tumor-targeted therapy. We demonstrate that the transient immunogenic tumor milieu contains more activated DC. This knowledge has important implications for the development of future combinatorial therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
- Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
- Malaghan Institute of Medical Research, Wellington, New Zealand.
- Department of Molecular Biology, Digital Science Center (DiSC), University of Innsbruck, Innsbruck, Austria.
- Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
- Institute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
ORCID-Profile: Zhe Fu, Christoph H Tripp, Zlatko Trajanoski, Marc Schmitz, Ian F Hermans, Patrizia Stoitzner
Förderung
- Austrian Science Fund FWF
- Österreichische Forschungsförderungsgesellschaft
- Österreichischen Akademie der Wissenschaften
- Austrian Science Fund
- Tiroler Wissenschaftsförderung
- Bundesministerium für Bildung und Forschung
- Christian Doppler Forschungsgesellschaft
- European Cooperation in Science and Technology
Zitieren
APA
Hornsteiner, F., Vierthaler, J., Strandt, H., Resag, A., Fu, Z., Ausserhofer, M., Tripp, C. H., Dieckmann, S., Kanduth, M., Farrand, K., Bregar, S., Nemati, N., Hermann-Kleiter, N., Seretis, A., Morla, S., Mullins, D., Finotello, F., Trajanoski, Z., Wollmann, G., …, & Stoitzner, P. (2024). Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008606
Vancouver
Hornsteiner F, Vierthaler J, Strandt H, Resag A, Fu Z, Ausserhofer M, et al. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008606
BibTeX
@article{Hornsteiner2024,
author = {Hornsteiner, Florian and Vierthaler, Janine and Strandt, Helen and Resag, Antonia and Fu, Zhe and Ausserhofer, Markus and Tripp, Christoph H and Dieckmann, Sophie and Kanduth, Markus and Farrand, Kathryn and Bregar, Sarah and Nemati, Niloofar and Hermann-Kleiter, Natascha and Seretis, Athanasios and Morla, Sudhir and Mullins, David and Finotello, Francesca and Trajanoski, Zlatko and Wollmann, Guido and Ronchese, Franca and Schmitz, Marc and Hermans, Ian F and Stoitzner, Patrizia},
title = {Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008606}
}
EUVIMED